Structure of human galactokinase in complex with galactose and 2'-(benzo[d]oxazol-2-ylamino)-7',8'-dihydro-1'H-spiro[cyclopentane-1,4'-quinazolin]-5'(6'H)-one

Structure of human galactokinase in complex with galactose and 2'-(benzo[d]oxazol-2-ylamino)-7',8'-dihydro-1'H-spiro[cyclopentane-1,4'-quinazolin]-5'(6'H)-one Descriptor: 2-(1,3-benzoxazol-2-ylamino)spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]-5-one, Galactokinase, beta-D-galactopyranose Authors: Bezerra, G.A, Mackinnon, S, Zhang, M, Foster, W, Bailey, H, Arrowsmith, C, Edwards, A, Bountra, C, Lai, K, Yue, W.W, Structural Genomics Consortium (SGC) Deposit date: 2020-06-17 Release date: 2021-06-30 Last modified: 2024-11-13 Method: X-RAY DIFFRACTION (2.439 Å) Cite: Fragment Screening Reveals Starting Points for Rational Design of Galactokinase 1 Inhibitors to Treat Classic Galactosemia. Acs Chem.Biol., 16, 2021

人半乳糖激酶（galactokinase）与半乳糖（galactose）及2'-(苯并[d]恶唑-2-基氨基)-7',8'-二氢-1'H-螺[环戊烷-1,4'-喹唑啉]-5'(6'H)-酮复合物的晶体结构。描述项：2-(1,3-苯并恶唑-2-基氨基)螺[1,6,7,8-四氢喹唑啉-4,1'-环戊烷]-5-酮、半乳糖激酶（galactokinase）、β-D-吡喃半乳糖（beta-D-galactopyranose）。作者：Bezerra, G.A.、Mackinnon, S、Zhang, M、Foster, W、Bailey, H、Arrowsmith, C、Edwards, A、Bountra, C、Lai, K、Yue, W.W、结构基因组学联盟（Structural Genomics Consortium, SGC）。存档日期：2020-06-17。发布日期：2021-06-30。最后修改日期：2024-11-13。实验方法：X射线衍射（X-RAY DIFFRACTION），分辨率2.439埃（Å）。引用文献：《Fragment Screening Reveals Starting Points for Rational Design of Galactokinase 1 Inhibitors to Treat Classic Galactosemia》，刊载于《ACS化学生物学》（Acs Chem.Biol.），第16卷，2021年。